Page 116 - TD-4-3
P. 116

Tumor Discovery                                                   BrECADD-induced ileus and GI hemorrhage



            physical condition, with an ECOG performance status of 0.   images. The patient agreed to the use of clinical details for
            His comorbidities were considered clinically insignificant.   academic  and  publication  purposes.  All  data  have  been
            Therefore, despite his age being over 60 years, we elected to   fully anonymized to protect the patient’s identity.
            proceed with the more intensive BrECADD regimen.
                                                               Availability of data
              As this case illustrates, careful patient selection is
            critical when considering intensive chemotherapy in older   Not applicable.
            or comorbid individuals, to minimize the risk of excessive
            toxicity, as was unfortunately observed in our patient.   References
            Based on this experience, we will adopt a more conservative   1.   Borchmann P, Ferdinandus J, Schneider G, et al. Assessing
            approach moving forward, reserving intensive regimens   the efficacy and tolerability of PET-guided BrECADD
            such as BrECADD for younger patients with adequate    versus eBEACOPP in advanced-stage, classical Hodgkin
            performance status and minimal comorbidity burden.    lymphoma (HD21): A  randomised, multicentre, parallel,
                                                                  open-label, phase 3 trial. Lancet. 2024;404(10450):341-352.
            4. Conclusion                                         doi: 10.1016/S0140-6736(24)01315-1

            This case report  highlights the rare  but potentially  life-  2.   German Hodgkin Study Group. Therapy - GHSG. Available
            threatening complication of chemotherapy-induced ileus   from: https://en.ghsg.org/treatment [Last accessed on
            in a patient  with AS-cHL treated  with  the  BrECADD   2025 Jun 08].
            regimen. Although GI toxicity, including diarrhea and   3.   Akbarali HI, Muchhala KH, Jessup DK, Cheatham S.
            mucositis, is well documented in chemotherapy, bowel   Chemotherapy induced gastrointestinal toxicities.  Adv
            obstruction  remains  an  uncommon  manifestation.  In   Cancer Res. 2022;155:131-166.
            this case, chemotherapy-induced enteritis likely triggered      doi: 10.1016/bs.acr.2022.02.007
            ileus, which was further complicated by GI hemorrhage
            and acute renal failure. Despite initial conservative   4.   Carraro F, Rivetti E, Romano E, Fagioli F. Two cases
            management, the patient required surgical intervention   of paralitic ileus in onco-hematologic patients.  Pediatr
                                                                  Rep. 2012;4(1):e3.
            due to recurrent bleeding. Our case demonstrates that
            careful patient selection is essential when considering      doi: 10.4081/pr.2012.e3
            intensive chemotherapy regimens such as BrECADD. Close   5.   Mourad AP, De Robles MS. Chemoimmunotherapy-related
            monitoring for GI symptoms is crucial during treatment.  enteritis resulting in a mechanical small bowel obstruction - a
                                                                  case report. Int J Surg Case Rep. 2021;79:131-134.
            Acknowledgments
                                                                  doi: 10.1016/j.ijscr.2020.12.096
            None.
                                                               6.   Jiao XD, Luo X, Qin WX, Yuan LY, Zang YS. Paralytic ileus
            Funding                                               due to a novel anticancer drug, nab-paclitaxel: A case report.
                                                                  Mol Clin Oncol. 2016;4(5):824-826.
            None.                                                 doi: 10.3892/mco.2016.782

            Conflict of interest                               7.   Roy R, Sarkar S. Paralytic ileus  -  a rare but serious
                                                                  side-effect of oral capecitabine.  Int J Anat Radiol Surg.
            The authors declare they have no competing interests.  2022;11(1):SC01-SC02.

            Author contributions                                  doi: 10.7860/IJARS/2022/56456.2843
            Conceptualization: Karl Mayrhofer                  8.   Kumar KS, Balaji P, Muppa L. Paralytic ileus as a rare
            Investigation: Karl Mayrhofer                         complication of vincristine therapy: A  case report.  Ind J
            Writing – original draft: Karl Mayrhofer              Pharm Pract. 2024;14(4):396-399.
            Writing – review & editing: Simon Udovica             doi: 10.5530/ijopp.17.4.65
                                                               9.   Balu A, Nagarajan T, Mudawi H. Chemotherapy induced
            Ethics approval and consent to participate            small bowel obstruction in small cell lung cancer.  Arab J
            Not applicable.                                       Gastroenterol. 2021;22(3):246-248.
                                                                  doi: 10.1016/j.ajg.2021.07.001
            Consent for publication
                                                               10.  European Medicines Agency.  Adcetris: EPAR  -  Product
            Informed consent was obtained from the patient for the   Information. Amsterdam: EMA; 2024. Available from:
            publication of this case report and any accompanying   https://www.ema.europa.eu/en/documents/product-


            Volume 4 Issue 3 (2025)                        108                           doi: 10.36922/TD025180033
   111   112   113   114   115   116   117   118   119   120   121